Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.55 |
| ▸ | GRM5 | P41594 | 11/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053191 | 0.84 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL31053177 | 0.82 | GRM1 (0.53) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL27025958 | 0.81 | NAMPT (0.52) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL30308912 | 0.79 | GRM1 (0.64) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL15553049 | 0.79 | PDK4 (0.53) | GRM1GRM5PDK4NAMPTHTR6 | |
| SCHEMBL25480230 | 0.78 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL31639564 | 0.78 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL30439311 | 0.78 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL903903 | 0.78 | GRM1 (0.56) | GRM1GRM5PDK4NAMPTWNT3A | |
| SCHEMBL15176153 | 0.78 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTWNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214495-A1 | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa | F10, F12, F11 | GRM1 2022/4885GRM5 2198/4885PDK4 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.